The group wants to improve on its own Welireg in a new phase 3 trial.
ApexOnco Front Page
Recent articles
Replimune gets a second chance, while Sarclisa could go subcutaneous.
But biomarker enrichment and toxicity remain key for FX-909.
Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
The company will license EGFR and cMet inhibitors from Celyn.
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
TARA-002 goes from looking better than Inlexzo to seeming rather worse.
After several discontinuations, a new ADC enters the clinic.
